
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health Inc. has reported a notable 5.3% volume growth in the non-oncology lab business, alongside a significant 20% increase in 4Kscore test volumes, indicating a strong demand for its diagnostic offerings. The company's BARDA-related revenue rose to $8.2 million, marking an improvement from $5.5 million in the prior year, suggesting enhanced performance in its pharmaceutical segment. Overall, the anticipated margin improvements in diagnostics, combined with effective cost-saving initiatives and a promising outlook for the 4Kscore diagnostic product, bolster a favorable financial perspective for OPKO Health.
Bears say
OPKO Health Inc. faced a significant operating loss of $18.3 million in its diagnostics segment during the recent quarter, contributing to a broader negative financial outlook. Additionally, the company's pharmaceutical product revenue declined to $37.7 million, down from $39.1 million the previous year, primarily due to lower sales volumes attributed to unfavorable customer timing and product mix. The disappointing financial guidance for FY/26, paired with a top-line revenue miss and increasing operating expenses, further supports the negative sentiment surrounding the company's stock.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares